Iressa

Iressa (gefitinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated as a first-line treatment in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Product Information – European Medicines Agency